New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Business Wire
Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)If approved, Gazyva would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activitySLE is a potentially life-threatening autoimmune disease that affects more than three million people worldwide SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva® (obinutuzumab) in adults with systemic lupus erythematosus (SLE) was published in the New England Journal of Medicine (NEJM). The study demonstrated a statistically significant and clinically meaningful benefit in the primary endpoint. Over three quarte
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche and Zealand's Phase II obesity trial divides analyst opinion [Yahoo! Finance]Yahoo! Finance
- New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity [Yahoo! Finance]Yahoo! Finance
- Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and ObesityBusiness Wire